Reduction in tumor burden has been previously demonstrated in a PCa xenograft model treated with concurrent HDAC/mTOR inhibition [19] and more recently in renal cell carcinoma (RCC) xenograft models [37]. Here, HDAC9 is linked to posterior cortical atrophy.